Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients Posted on June 24, 2020, in News, Press Releases wp_link_pages( array( 'before' => ' ' . esc_html__( 'Pages:', 'gridtherapeutics' ), 'after' => ' ', ) ); ?> Read more